Trial Profile
Effect of switching therapy from nucleos(t)ide analogue to pegylated-interferon in patients with chronic hepatitis B
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2019
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Therapeutic Use
- 03 Dec 2013 New trial record